retatrutide clinical trial results retatrutide First phase 3 data, a Triumph of Science! Michael Weintraub, MD on X:

Background There were two GLP-1 products that were initially approved and marketed for treating type-2 diabetes but, because they also had successful weight loss results, the manufacturers each got FDA approval to sell the products under two separate indications, one indicated for type 2 diabetes and one for weight loss, each with its own brand name and National Drug Code (NDC) identification number

Cardiology 106(4):215223

Nutrition and Nourishment Collective

In che modo l'integrazione alimentare di L-carnitina influisce sui livelli di carnitina

GLP-1 is the naturally occurring agonist for GLP-1 receptors

eds.), pp 11435